



Duncombe, A. S., Anderson, L. A., James, G., de Vocht, F., Fritschi, L., Mesa, R., Clarke, M., & McMullin, M. F. (2020). Modifiable lifestyle and medical risk factors associated with myeloproliferative neoplasms. *HemaSphere*, 4(1). <https://doi.org/10.1097/HS9.0000000000000327>

Publisher's PDF, also known as Version of record

License (if available):
CC BY-NC-ND

Link to published version (if available):
[10.1097/HS9.0000000000000327](https://doi.org/10.1097/HS9.0000000000000327)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the final published version of the article (version of record). It first appeared online via Lippincott, Williams & Wilkins at https://journals.lww.com/hemasphere/Fulltext/2020/02000/Modifiable_Lifestyle_and_Medical_Risk_Factors.4.aspx. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: <http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

risks.^{11,13} While smoking and alcohol were not associated with MPNs in these small case control studies,^{13,17} current smoking, increasing body mass index (BMI), and lower physical activity levels were positively associated with some MPN subtypes in recent cohort studies.^{18–20} To investigate potential risk factors further we undertook an exploratory case-control study in the United Kingdom (UK).

Methods

The exploratory MOSAICC (Myeloproliferative Neoplasms: An In-depth Case-Control) study aimed to identify appropriate methodological approaches to roll-out a large UK-wide case-control study of MPNs. MPN patients were recruited from 2 sites: Belfast City Hospital, Belfast and University Hospital Southampton NHS Foundation Trust, Southampton. Eligible patients, identified by their lead consultant (MFMcM and ASD), were classified according to the WHO diagnostic criteria.²¹ A study information pack was provided containing a consent form, study information booklet and a MPN-Symptom Assessment Form.²² Patients were asked to recruit non-blood relative or friend (NBR/F) controls to the study by providing them with information flyers. Age (5-year age band) and gender frequency-matched General Practice (GP) controls were also recruited. Patients were ineligible if they were < 18 years of age or were incapable of giving informed consent or were physically or cognitively incapable of completing a telephone interview. Participants underwent a structured telephone interview (average interview time: 45 minutes) with a trained interviewer using a questionnaire designed to identify medical and lifestyle risk factors. Ethical approval was obtained from the Office for Research Ethics Committee, Northern Ireland (ORECNI 12/NI/0165).

Data was collected on gender, age (dichotomized to < 60 and ≥ 60 years), recruiting clinic (Belfast/Southampton), ethnicity (Caucasian vs other) and Jewish ancestry. Childhood socio-economic position (SEP), based on main household occupation, was classified using the Standard Occupational Classification system from highest¹ to lowest⁵ social class.²³ Birth order and number of siblings (termed sibship size) were requested with childhood household density calculated by dividing the number of children by the number of bedrooms in the childhood home. Level of education was categorized as none- GCSE/O-level or A-level or higher or equivalents. Pack years of smoking was calculated by dividing average number of cigarettes smoked/day by 20 and multiplying by years of smoking. Alcohol consumption was measured by the average number of units of wine, beer or spirits consumed per week within or above the UK Drinkaware guidelines.²⁴ Self-reported weight and height were used to calculate BMI with classification according to the World Health Organization criteria (underweight: < 18.5 kg/m², normal weight: 18.5–24.99 kg/m², overweight: 25–29.99 kg/m², obese/severely obese: ≥ 30 kg/m²).²⁵ Questions included self-reported piercings, tattoos, tooth fillings, implants (metal plates, silicone implants etc.) and hair dye use. Current information on use and storage of chemicals within the home in addition to hobbies and air travel was also obtained. Additionally, a range of pre-existing medical conditions identified in the systematic review¹⁰ was investigated.

Statistical analysis

Variables were compared between GP and NBR/F controls using unconditional logistic regression. Multivariate logistic regression models comparing MPN patients to all controls were adjusted for age, gender and clinic (location) producing adjusted

Table 1

Demographic Characteristics of Participants

Variable	Controls n (%)	MPN Cases n (%)	Unadjusted Odds ratio (95% CI)
Age group			
<60 years	43 (35.8)	33 (31.1)	1.00
≥60 years	77 (64.2)	73 (68.9)	1.24 (0.71–2.15)
Gender			
Male	46 (38.3)	42 (39.6)	1.00
Female	74 (61.7)	64 (60.4)	0.95 (0.55–1.62)
Clinic			
Southampton	72 (60.0%)	66 (62.3)	1.00
Belfast	48 (40%)	40 (37.7)	0.91 (0.53–1.55)
Ethnicity			
Caucasian	116 (96.7)	102 (96.2)	1.00
Other	4 (3.3)	4 (3.8)	1.14 (0.28–4.66)
Jewish			
No	119 (99.2)	102 (96.2)	1.00
Yes	1 (0.83)	2 (1.89)	2.33 (0.21–26.11)
Don't know	0 (0)	2 (0.88)	–

odds ratios (ORs) and corresponding 95% confidence intervals (CIs). Tests for trend were used to determine significance per category increase of the exposure/variable. A backwards stepwise logistic regression analysis was constructed including associations significant at $p < 0.010$ to identify key risk factors. Statistical analyses were performed using STATA 12.0TM (StataCorp, College Station, TX).

Results

In total, 106 MPN cases and 120 controls were included in these analyses representing overall participation rates of 66.7% and 32.3%, respectively. Rates were much lower in GP vs NBR/F controls; 17.0% and 72.5%, respectively. After adjustment for age, gender, clinic and education, GP controls were less likely to be female ($p = 0.009$), to have tooth fillings ($p = 0.001$) and more likely to have asthma ($p = 0.045$) than NBR/F controls. The control groups did not differ in regard to any of the other exposures assessed and we therefore combined the 2 groups for analysis.

Mean age did not significantly differ between cases [63.3 years, standard deviation (SD) 12.5 years] and controls (60.5 years, SD 12.4 years), $p = 0.093$. Compared to all controls MPN cases did not significantly differ with regard to any of the participant characteristics reported in Table 1. The distribution of patients within the 3 subtypes of MPN is shown in Table 2. Of the MPN cases 71 (67.0%) were JAK2 positive.

Childhood factors

MPN patients were more likely than controls (all or either subgroup) to have been raised in a household where the main occupation was of a lower socio-economic status, (OR 2.30, 95% CI 1.02–5.18). There was trend for MPN patients to have

Table 2

Distribution of Patients Between the 3 Disease Subtypes

MPN subtype	Number	%
PV	37	34.9
ET	55	51.9
PMF	14	13.2

Table 3**Socioeconomic Position in Childhood and Related Childhood Exposures in Patients with MPNs Compared to Controls.**

Variable	Controls n (%)	MPN cases n (%)	OR* (95% CI)
Socio-economic position of head of household as child			
1 (highest)	38 (31.7)	16 (15.4)	1.00
2	24 (20.0)	29 (27.9)	2.88 (1.29–6.44)
3	8 (6.7)	6 (5.8)	1.78 (0.52–6.07)
4	25 (20.8)	28 (26.9)	2.59 (1.16–5.78)
5 (lowest)	25 (20.8)	25 (24.0)	2.30 (1.02–5.18)
<i>p for trend</i>			0.091
Birth Order			
Other	72 (60.0)	48 (40.0)	1.00
Firstborn	71 (67.0)	35 (33.0)	0.71 (0.41–1.23)
Sibship size			
0/1	50 (41.7)	43 (40.6)	1.00
2	32 (26.7)	23 (21.7)	0.86 (0.44–1.71)
3–4	23 (19.2)	26 (24.5)	1.38 (0.67–2.80)
5 or more	15 (12.5)	14 (13.2)	1.14 (0.49–2.64)
<i>p for trend</i>			0.516
Childhood household density			
<1 child/bedroom	28 (23.3)	11 (10.4)	1.00
1 child/bedroom	29 (24.2)	33 (31.1)	3.12 (1.30–7.48)
2 or more children/ bedroom	63 (52.5)	62 (58.5)	2.55 (1.16–5.62)
<i>p for trend</i>			0.069
Attended Nursery/playschool/preschool			
No	90 (75.0)	83 (79.1)	1.00
Yes	30 (25.0)	22 (21.0)	0.82 (0.43–1.58)
Education			
None- GCSE/O-level	41 (34.2)	48 (45.3)	1.00
A-level or higher	79 (65.8)	56 (52.8)	0.62 (0.36–1.06)
Don't know	0 (0)	2 (1.9)	–

* Adjusted for age (5 year age bands), gender, site location (Southampton/Belfast) and education (category).

experienced higher childhood household density than controls (OR 2.55, 95% CI 1.16–5.62), although this trend did not reach significance, Table 3.

Lifestyle factors

Current cigarette smoking was more common in cases than controls but statistical significance was only observed in those who had the highest pack years of smoking, (OR 2.19 95%CI 1.03–4.66, $p=0.01$; Table 4. Current smoking status was significantly elevated for PV cases only (OR 3.73, 95% CI 1.06–13.15) Table 5.

Alcohol consumption was inversely associated with MPNs, in PV (OR 0.41, 95% CI 0.19–0.92) and ET (OR 0.48, 95% CI 0.24–0.98) but not MF (OR 1.03, 95% CI 0.26–4.11). Risk of MPNs did not significantly differ by alcohol type consumed; wine (OR 0.90, 95% CI 0.49–1.64), beer (OR 0.81, 95% CI 0.30–2.17) and spirits (OR 0.41, 95% CI 0.08–2.21) Tables 4 and 5.

While obesity appeared to elevate overall MPN risk it was not significant, Table 4. However, when stratified by MPN subtype, obesity was significantly associated with ET (OR 2.59, 95% CI 1.02–6.58) only, Table 5. There were no significant associations between piercings, tattoos, implants or hair dying and MPNs, Table 4.

Environmental factors/other

There were no significant associations between use of potential household carcinogens and excess MPN risk. Painting in home

Table 4**Lifestyle Risk Factors and Association with Myeloproliferative Neoplasms (MPN) Compared to Controls.**

Variable	Controls n (%)	MPN Cases n (%)	OR* (95% CI)
Cigarette smoking			
Never	69 (57.5)	51 (48.1)	1.00
Former	45 (37.5)	46 (43.4)	1.35 (0.77–2.35)
Current	6 (5.0)	9 (8.49)	2.13 (0.71–6.42)
<20 pack years	35 (29.4)	30 (28.6)	1.14 (0.62–2.10)
≥20 pack years	15 (12.6)	24 (22.9)	2.19 (1.03–4.66)
<i>p for trend (pack years)</i>			0.010
Alcohol			
Never	27 (22.5)	41 (38.7)	1.00
Ever	93 (77.5)	65 (61.3)	0.48 (0.27–0.86)
Within Drinkaware guidelines ^s	66 (55.0)	48 (45.3)	0.50 (0.27–0.93)
Above Drinkaware guidelines ^s	27 (22.5)	17 (16.0)	0.42 (0.19–0.93)
Body mass index (current)			
Underweight	2 (1.68)	3 (2.83)	1.96 (0.31–12.3)
Normal	57 (47.9)	44 (41.5)	1.00
Overweight	45 (37.8)	37 (34.9)	1.05 (0.58–1.89)
Obese	15 (12.61)	22 (20.8)	1.97 (0.91–4.25)
<i>p for trend (Norm-Obese)</i>			0.201
Body mass index (10 years)			
Underweight	3 (2.54)	2 (1.92)	0.95 (0.15–6.08)
Normal	70 (59.3)	56 (41.5)	1.00
Overweight	40 (33.9)	36 (34.6)	0.96 (0.48–1.95)
Obese	5 (4.24)	10 (9.62)	2.53 (0.85–7.57)
<i>p for trend (Norm-Obese)</i>			0.315
Piercings			
No	56 (46.7)	64 (53.3)	1.00
Yes	49 (46.2)	57 (53.8)	1.31 (0.59–2.91)
Tattoos			
No	108 (90.0)	99 (93.4)	1.00
Yes	12 (10)	7 (6.6)	0.59 (0.20–1.69)
Tooth Fillings			
No	53 (44.2)	36 (34.0)	1.00
Yes	67 (55.8)	70 (66.0)	1.29 (0.75–2.23)
Implants			
No	106 (88.3)	90 (84.9)	1.00
Yes	14 (11.7)	16 (15.1)	1.28 (0.58–2.81)
Hair Dye			
No	55 (45.8)	51 (48.1)	1.00
Yes	65 (54.2)	55 (51.9)	0.94 (0.42–2.10)
Dark dye	40 (33.3)	36 (34.0)	1.07 (0.55–2.07)
Self-administered	43 (35.8)	28 (26.4)	0.60 (0.31–1.15)
Dyed by someone else	48 (40.0)	46 (43.4)	1.46 (0.71–2.98)
Bleached			
No	92 (76.7)	74 (69.8)	1.00
Yes	28 (23.3)	32 (30.2)	1.66 (0.86–3.21)

decorating was less commonly reported among MPN patients than controls, (OR 0.44, 95%CI 0.25–0.79) Table 6. The majority (>90%) of participants had had pets but there was no significant difference overall between cases and controls (OR 0.90, 95% CI 0.37–2.17). Of all animal types investigated only pig ownership was higher among cases than controls, 8 (7.5%) vs 2 (1.7%) (OR 5.62, 95% CI 1.13–28.0). Low absolute numbers precluded further multivariate analysis and larger studies will be needed to determine whether this is a genuine risk factor.

There were no significant associations seen with a number of other putative environmental risk factors including the use of home solvents, paints, bleach, oven cleaner, garden herbicides or pesticides, frequency of boiler maintenance or home car mechanical work. Also, no differences between cases and

Table 5**Association Between Smoking, Alcohol and Body Mass Index and Myeloproliferative Neoplasm (MPN) Subtypes.**

Variable	Controls	Polycythaemia vera		Essential thrombocythaemia		Primary Myelofibrosis	
	n (%)	n (%)	OR (95% CI)	n (%)	OR (95% CI)	n (%)	OR (95% CI)
Cigarette smoking							
Never	69 (57.5)	18 (48.7)	1.00	28 (50.9)	1.00	5 (35.7)	1.00
Former	45 (37.5)	13 (35.1)	1.06 (0.47–2.41)	25 (45.5)	1.39 (0.71–2.72)	8 (57.1)	1.90 (0.53–6.79)
Current	6 (5.0)	6 (16.2)	3.73 (1.06–13.1)	2 (3.6)	0.86 (0.16–4.59)	1 (7.1)	1.50 (0.11–20.7)
Alcohol							
Never	27 (22.5)	15 (40.5)	1.00	22 (40.0)	1.00	4 (28.6)	1.00
Ever	93 (77.5)	22 (59.5)	0.41 (0.19–0.92)	33 (60.0)	0.48 (0.24–0.98)	10 (71.4)	1.03 (0.26–4.11)
Body mass index (current)							
Underweight	2 (1.68)	1 (2.7)	1.28 (0.11–15.62)	2 (3.6)	3.16 (0.41–24.2)	0	-
Normal	57 (47.9)	19 (51.4)	1.00	19 (34.6)	1.00	6 (42.9)	1.00
Overweight	45 (37.8)	10 (27.0)	0.61 (0.25–4.62)	22 (40.0)	1.55 (0.73–3.28)	5 (35.7)	0.71 (0.18–2.82)
Obese	15 (12.61)	7 (18.9)	1.38 (0.48–3.94)	12 (21.8)	2.59 (1.02–6.58)	3 (21.4)	1.26 (0.21–7.44)

*Adjusted for age (5 year age bands), gender, site location (Southampton/Belfast) and education (category).

controls were seen in the frequency of short or long haul flights taken per year.

Medical history

There were no significant associations between any of the medical conditions (diagnosed before MPN diagnosis) and MPNs, Table 6. Of the medical procedures investigated only the frequency of CT scans was associated with an increased risk of MPNs, Table 6. Patients receiving 3 or more CT scans had OR of 5.38 (95%CI 1.67–17.3). There was no difference between cases and controls by any CT sites (data not shown) or by the proportion of cases having had a CT scan by clinic. MPN patients and controls reported having had CT scans of their full body (n = 9 cases vs 9 controls), head and neck (n = 15 vs 12), back (n = 2 vs 3), chest (n = 9 vs 4), abdomen (n = 18 vs 17), groin (n = 3 vs 0) and legs/arms (n = 6 vs 6).

Multivariate model

In the backwards multivariate regression model, smoking >20 pack years, (OR 2.69, 95% CI 1.26–5.74) and childhood household density (Intermediate vs low: OR 2.35, 95% CI 1.01–5.45); high vs low: OR 2.34, 95% CI 1.26–5.74) remained significantly associated with increased risk of MPNs. Alcohol (OR 0.50, 95% CI 0.27–0.94) and household painting (OR 0.42, 95% CI 0.23–0.76) remained inversely associated with MPNs.

Discussion

In this exploratory case-control study, we confirmed associations between MPNs and smoking and obesity (for ET patients only) and identified other potential risk factors including childhood household crowding and receipt of multiple CT scans.

Childhood circumstances may influence chronic diseases in later life. Lower childhood SEP has been associated with increased cancer mortality rates for smoking-related cancers in some studies potentially mediated in part by lifestyle choices and SEP in later life.²⁶ When adjusted for potential confounding factors, including years of formal education, we identified that lower childhood SEP was associated with an increased risk of MPNs potentially mediated via similar mechanisms. Indeed, when we ran a multivariate model with backwards selection of significant exposure variables, child-

hood household density remained significantly associated with MPNs. There was also a borderline association between higher educational attainment and reduced risk of MPNs which could point towards occupational exposures or lifestyle risk behaviors.

In keeping with the recent Million Women Study^{18,19} and Iowa Women's Health Study²⁰ smoking 20 or more pack years of cigarettes was associated with an increased risk of MPN in our study. Supporting the findings from The Iowa Women's Health Study we identified that the association with current smoking was limited to patients with PV.²⁰ As the previous study used medical claims data, misclassification of cases presenting with secondary or apparent polycythemia as a result of smoking, may have occurred.²⁷ In contrast, we had a defined case identification process ensuring only primary PV patients were included in the study and confirmed the association was limited to PV cases. Studies have demonstrated a link between current smoking status and increased *JAK2_{v617F}* mutations, potentially through activation of the JAK pathway via inflammatory processes.^{28–30} Given that the majority of PV patients had *JAK2_{v617F}* mutation present (94.6%), while only 56.4% and 35.7% of ET and PMF patients were *JAK2_{v617F}* positive; this could explain the observed differences by MPN subgroup. We were unable to confirm this due to limited power but the ORs were higher compared to controls for JAK2 positive (OR 2.58) than for JAK2 negative (OR 1.70) cases.

Two cohorts also investigated the association between BMI and MPNs. In the Million Women Study, obese women had a 33% increased risk of MPNs.¹⁹ While we did not observe an overall statistically significant association we observed a similar increase in obese individuals. In keeping with our findings, the Iowa Women's Study reported that increasing BMI was associated with a significantly increased risk of ET but not PV.²⁰ They also reported an increased risk of ET among diabetics although we did not replicate this in the current study. It has been speculated that similar pathways may link obesity and thrombocytosis. In mice studies deletion of Signal transducer and activator of transcription (STAT)3 in the central nervous system leads to obesity and diabetes in homozygous mutants³¹ and deletion of STAT3 in hematopoietic cells enhances thrombocytosis in *JAK2_{v617F}* mouse models.³² The exact mechanism of action however requires further investigation.

Alcohol was inversely associated with MPNs in this study but has not previously been associated with MPNs.^{17–19} Alcohol

Table 6
Medical Conditions and Exposures Compared Between Myelo-proliferative Neoplasm (MPN) Cases and Controls.

Variable	Controls n (%)	Cases n (%)	OR* (95% CI)
Rheumatoid Arthritis [§]			
No	118 (98.3)	104 (98.1)	1.00
Yes	2 (1.7)	2 (1.9)	1.12 (0.15–8.32)
Diabetes [§]			
No	113 (94.2)	104 (92.5)	1.00
Yes	7 (5.8)	8 (7.6)	1.33 (0.46–3.82)
Pneumonia [§]			
No	108 (90.0)	96 (90.6)	1.00
Yes	12 (10.0)	8 (7.6)	0.71 (0.27–1.85)
Shingles [§]			
No	103 (85.8)	95 (92.2)	1.00
Yes	17 (14.2)	8 (7.8)	0.44 (0.17–1.11)
Allergies [§]			
No	76 (63.3)	77 (72.6)	1.00
Yes	44 (36.7)	29 (27.4)	0.67 (0.38–1.18)
Asthma [§]			
No	101 (84.2)	92 (86.8)	1.00
Yes	19 (15.8)	14 (13.2)	0.82 (0.39–1.74)
Psoriasis [§]			
No	112 (93.3)	103 (97.2)	1.00
Yes	8 (6.7)	3 (2.8)	0.41 (0.11–1.61)
Hypertension [§]			
No	84 (70.0)	76 (73.1)	1.00
Yes	36 (30.0)	28 (26.9)	0.80 (0.44–1.46)
Heart Disease [§]			
No	115 (95.8)	98 (92.5)	1.00
Yes	5 (4.2)	8 (7.6)	1.84 (0.57–5.91)
Blood Transfusion			
No	95 (80.5)	75 (72.8)	1.00
Yes	23 (19.5)	28 (27.2)	1.56 (0.82–2.97)
X-rays			
0–5	22 (18.3)	27 (25.5)	1.00
6–15	52 (43.3)	41 (38.7)	0.64 (0.31–1.33)
>15	46 (38.3)	38 (35.9)	0.65 (0.31–1.39)
CT scans			
0	71 (60.2)	53 (52.0)	1.00
1–2	43 (36.4)	33 (32.4)	1.06 (0.59–1.90)
≥3	4 (3.4)	16 (15.7)	5.38 (1.67–17.3)
PV (>3)	4 (3.4)	6 (16.2)	5.62 (1.36–23.2)
ET (>3)	4 (3.4)	5 (9.1)	3.42 (0.82–14.2)
PMF (>3)	4 (3.4)	5 (35.7)	15.3 (2.11–110.5)
Blood Donation			
No	59 (49.2)	60 (56.6)	1.00
Yes	61 (50.8)	46 (43.4)	0.78 (0.45–1.33)

Numbers may not add up to the total number of participants as some participants did not know/did not report if they had ever been diagnosed with the disease in question and were recorded as missing.

* Adjusted for age (5 year age bands), gender, site location (Southampton/Belfast), and education (category).

§ Diagnosis pre-MPN diagnosis in cases.

consumption has, however, been inversely associated with other hematological neoplasms including lymphoma^{33,34} and leukaemia.³⁴ We asked about lifetime alcohol consumption and MPN patients may have altered their alcohol consumption post-diagnosis resulting in potential recall bias. While the risk reduction may be due to reverse causality, resveratrol, found in red wine, may reduce the risk of lymphoma³⁵ and has been shown to inhibit proliferation and induce apoptosis in malignant cell lines with *JAK2*_{V617F} mutation.³⁶ We did not observe any significant differences in MPN risk by alcohol type (wine, beer, spirits) consumed but sample size was limited. Further evaluation

of the potential interaction between alcohol and the JAK pathway is warranted.

Painting in decorating at home was inversely associated with MPNs. While multiple testing could explain this as a chance association, MPN patients may be less likely to paint due to the fatigue that they experience from their MPN. While reverse causation cannot be ruled out we asked whether the patients had ever painted with the association remaining in the multivariate model. The strong positive association between pig ownership and MPNs has not previously been reported. While it is likely a chance association due to multiple testing, further clarifications of the association in a larger, suitably powered, study is merited.

Exposure to radiation from CT scans has been reported to increase the risk of developing a number of cancers including leukaemia.³⁷ We found that compared with controls, MPN patients were more likely to have received three or more CT scans, particularly those with PV. The elevated ORs in our study may have resulted in part due to the use of CT scans during the diagnostic work-up or evaluation of MPN patients. However, CT scans are generally not used for PV or ET diagnosis. Further evaluation of the case clinical notes was not available for validation and timing of CT scans so we cannot confirm whether or not all CT scans were pre-diagnosis. If there is a causal relationship, then the recent introduction of lower dose CT is likely to reduce the potential carcinogenic effects. Optimization of the CT image at lower doses and limiting CT scans on the basis of clinical need is important to reduce potential harmful effects.

Other potential risk factors identified in our previous systematic review of MPNs included blood donation, dark hair dye use and some autoimmune conditions.¹⁰ Although previous studies suggested higher PV risk among blood donors,^{38,39} this was not substantiated in a recent cohort of 1.4 million blood donors⁴⁰ in keeping with the results of the current study. We also found no association between dark hair dye use and MPNs or with any of the autoimmune conditions evaluated.

Given the rarity of MPNs, this is the largest case-control study to date. We evaluated 2 control groups, GP and NBR/F controls, and found little difference between groups for most variables assessed. NBR/F controls were more convenient and less expensive to recruit and are useful for rare diseases where patients are referred to secondary or tertiary care.⁴¹ While it is acknowledged that there are limitations with this method as it may lead to closer matching of the case and control populations, similar characteristics would actually attenuate observed associations rather than create erroneous associations.⁴² Even with modest numbers, our exploratory study demonstrated significant differences in several parameters under investigation between cases and NBR/F controls despite the likelihood of shared factors. However, our study is likely underpowered to detect small differences in MPN risk and a large co-ordinated study to evaluate risk factors associated with MPNs, to enable stratification by subtype, is warranted.

In conclusion, this exploratory case-control study confirms a reported association between cigarette smoking and PV. We also identified an increased risk of ET in patients defined as obese according to the WHO classification system. Further investigation of the relationship between CT scans and alcohol consumption with MPNs may help in the identification of the causal pathways that lead to acquisition of acquired mutations such as *JAK2* in patients with MPNs. While this exploratory study is the largest case-control study of MPNs reported to date in the worldwide literature, replication in a larger case-control study is required to confirm or refute our findings.

Acknowledgements

We thank all the participants who contributed to the study. The work was supported by Queen's University Belfast's Centre for Public Health. The MOSAICC Study team acknowledges the support of the National Institute for Health Research, through the Northern Ireland Cancer Research Network (NICRN) and for Southampton, the Wessex Cancer Research Network. The MOSAICC Study team also acknowledges the support of research nurses Emma Gaunt of Southampton and Claire Leathem of Belfast. The interpretation and reporting of these data are the sole responsibility of the authors.

References

1. Titmarsh GJ, Duncombe AS, McMullin MF, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. *Am J Hematol*. 2014;89:581–587.
2. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. *Lancet*. 2005;365:1054–1061.
3. Pardanani A, Lasho TL, Finke CM, et al. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. *J Clin Oncol*. 2012;30:1087–1094.
4. Thorsten , Klampfl , Heinz Gisslinger , et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. *NEJM*. 2013; 369:2391–2405.
5. Nangalia J, Massie CE, Baxter EJ, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. *NEJM*. 2013;369:2379–2390.
6. Shen M, Purdue MP, Krickler A, et al. Polymorphisms in DNA repair genes and risk of non-Hodgkin's lymphoma in New South Wales, Australia. *Haematologica*. 2007;92:1180–1185.
7. Hayden PJ, Tewari P, Morris DW, et al. Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma. *Hum Mol Genet*. 2007;16:3117–3127.
8. Rudd MF, Sellick GS, Webb EL, et al. Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia. *Blood*. 2006;108:638–644.
9. Gross-Davis CA, Heavner K, Frank AL, et al. The role of genotypes that modify the toxicity of chemical mutagens in the risk for myeloproliferative neoplasms. *Int J Environ Res Public Heal*. 2015;12:2465–2485.
10. Anderson LA, Duncombe AS, Hughes M, et al. Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. *Am J Hematol*. 2012;87:175–182.
11. Exposure to occupational and environmental risk factors in hematological disorders. *Neoplasia*. 1997;14:133–136.
12. Falcetta R, Sacerdote C, Bazzan M, et al. Occupational and environmental risk factors for essential thrombocythemia: a case-control study. *G Ital Med Lav Ergon*. 2003;25 (Suppl (3)):9–12.
13. Pasqualetti P, Casale R, Colantonio D, et al. Occupational risk for hematological malignancies. *Am J Hematol [Internet]*. 1991;38:147–149. Oct [cited 2014 Feb 27]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/1951308>.
14. Giles GG, Lickiss JN, Baikie MJ, et al. Myeloproliferative and lymphoproliferative disorders in Tasmania, 1972–80: occupational and familial aspects. *J Natl Cancer Inst*. 1984;72:1233–1240. Jun [cited 2014 Feb 27]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/6587145>.
15. Quiroga Micheo E, Calcagno EJ, Calabria SI, et al. Retrospective epidemiological study of hemopoietic system neoplasms in Argentina. *Medicina (B Aires) [Internet]*. 1981;41:187–200. Jan [cited 2014 Feb 27]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/7278616>.
16. Karyn Heavner IB. Working environment and myeloproliferative neoplasm: a population-based case-control study following a cluster investigation. *Am J Ind Med*. 2015;58:595–604.
17. Mele A, Visani G, Pulsoni A, et al. Risk factors for essential thrombocythemia: a case-control study. Italian Leukemia Study Group. *Cancer*. 1996;77:2157–2161.
18. Kroll ME, Murphy F, Pirie K, et al. Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK Million Women Study. *Br J Cancer*. 2012;107:879–887.
19. Murphy F, Kroll ME, Pirie K, et al. Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study. *Br J Cancer*. 2013;108:2390–2398.
20. Leal AD, Thompson CA, Wang AH, et al. Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in The Iowa Women's Health Study cohort. *Int J Cancer*. 2014;134:1741–1750.
21. McMullin MF, Reilly JT, Campbell P, et al. Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. *Br J Haematol*. 2007;138:821–822.
22. Anderson LA, James G, Duncombe AS, et al. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. *Am J Hematol*. 2015; 90:864–870.
23. AAAS Employment Department Group O of PC and S. Standard occupational classification. London: HMSO; 1990.
24. Drinkaware. Alcohol limits and units guidelines [Internet]. 2016 [cited 2016 Nov 18]. Available from: <https://www.drinkaware.co.uk/alcohol-facts/alcoholic-drinks-units/alcohol-limits-unit-guidelines/>
25. World Health Organization. Physical status: the use and interpretation of anthropometry Report of a WHO Expert Committee. Technical Report Series No. 854. Available from: http://www.who.int/childdgrowth/publications/physical_status/en/
26. Galobardes B, Lynch JW, Davey Smith G. Childhood socioeconomic circumstances and cause-specific mortality in adulthood: systematic review and interpretation. *Epidemiol Rev*. 2004;26:7–21.
27. Sagone AL, Balcerzak SP. Smoking as a cause of erythrocytosis. *Ann Intern Med*. 1975;82:512–515.
28. Nielsen C, Birgens HS, Nordestgaard BG, et al. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population. *Br J Haematol*. 2013;160:70–79.
29. Weinberg I, Borohovitz A, Krichevsky S, et al. Janus Kinase V617F mutation in cigarette smokers. *Am J Hematol*. 2012;87:5–8.
30. Lekovic D, Gotic M, Perunicic-Jovanovic M, et al. Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis. *Med Oncol*. 2014;31: 869.
31. Gao Q, Wolfgang MJ, Neschen S, et al. Disruption of neural signal transducer and activator of transcription 3 causes obesity, diabetes, infertility, and thermal dysregulation. *Proc Natl Acad Sci USA*. 2004;101:4661–4666.
32. Grisouard J, Shimizu T, Duek A, et al. Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN. *Blood*. 2015;125:2131–2140.
33. Gapstur SM, Diver WR, McCullough ML, et al. Alcohol intake and the incidence of non-hodgkin lymphoid neoplasms in the cancer prevention study II nutrition cohort. *Am J Epidemiol*. 2012;176:60–69.
34. Ji J, Sundquist J, Sundquist K. Alcohol consumption has a protective effect against hematological malignancies: a population-based study in Sweden including 420,489 individuals with alcohol use disorders. *Neoplasia*. 2014;16:229–234. 234.e1.
35. Wieder T, Prokop A, Bagci B, et al. Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. *Leukemia*. 2001;15:1735–1742.
36. Trung LQ, Espinoza JL, An DT, et al. Resveratrol selectively induces apoptosis in malignant cells with the JAK2V617F mutation by inhibiting the JAK2 pathway. *Mol Nutr Food Res*. 2015;59:2143–2154.
37. Berrington de Gonzalez A, Salotti JA, McHugh K, et al. Relationship between paediatric CT scans and subsequent risk of leukaemia and brain tumours: assessment of the impact of underlying conditions. *Br J Cancer*. 2016;114:388–394.
38. Najean Y, Rain JD, Billotey C. Epidemiological data in polycythaemia vera: a study of 842 cases. *Hematol Cell Ther*. 1998;40:159–165.
39. Merk K, Mattsson B, Mattsson A, et al. The incidence of cancer among blood donors. *Int J Epidemiol*. 1990;19:505–509.
40. Edgren G, Nyrén O, Hultcrantz M, et al. Blood donation and risk of polycythemia vera. *Transfusion*. 2016;56 (Pt 2):1622–1627.
41. Davis F, Il'yasova D, Rankin K, et al. Medical diagnostic radiation exposures and risk of gliomas. *Radiat Res*. 2011;175:790–796.
42. Bunin GR, Vardhanabhuti S, Lin A, et al. Practical and analytical aspects of using friend controls in case-control studies: experience from a case-control study of childhood cancer. *Paediatr Perinat Epidemiol*. 2011;25:402–412.